ERBB2 and breast cancer: In 96 HER2-enriched breast cancer patients, we observed that high STAT3 activation and high JAK2-STAT3/TrkA co-activation, but not high TrkA activation, correlate with a shortened time to develop overall metastasis (Figure 5B).